Abstract

(COVID-19) Corona virus disease 2019 is related to severe lung damage and it is likely to cause multi-organ failure, finding a definitive treatment challenging researchers worldwide. Recently dexamethasone has demonstrated significant effects in COVID-19; it reduced mortality and improved recovery. It suppresses immune response and inhibits inflammatory factors, and hence it reduces inflammation and prevents progression to severe form of COVID-19 that caused by excessive cytokine release. Indeed, current evidence about dexamethasone role in the management of COVID-19 is insufficient. The pathophysiology of COVID-19 and dexamethasone action are key points behind its contribution in the treatment of this panepidemic.